Chief Executive Officer · Rani Therapeutics Holdings, Inc. (RANI)

Talat Imran

A named executive officer of Rani Therapeutics in every fiscal year CompBrief holds from FY2024 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$1,052,101

Salary $198,325Stock awards $0

FY2024: $3,042,245

1st of 3 named executive officers at Rani Therapeutics by FY2025 total.

3 named officers on file for Rani Therapeutics, FY2025

Talat Imran’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Rani Therapeutics’s whole pay program stands against its peers

  • Rani Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RANI→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 16, 2026 (DEF 14A).

Free

Get Talat Imran’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Talat Imran compensation by year

Rani Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Rani Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024FY2025
Salary$105,818$198,325
Bonus$0$0
Stock awards$0$0
Option awards$2,936,227$502,176
Non-equity incentive$0$351,600
Pension and deferred compensation$0$0
All other$0$0
Total$3,042,245$1,052,101

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Rani Therapeutics Holdings, Inc. DEF 14A filed April 16, 2026, accession 0001140361-26-015157, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Rani Therapeutics Holdings, Inc. filed document, accession 0001140361-26-015157. Every figure is read from that document and cited to the page and table it appears in. Filed April 16, 2026.

$3.0M
$1.1M
FY24
FY25
SalaryNon-equity incentiveOption awards

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU110,469$149,133—
RSU21,650$29,228—
Option899,438—$0.62
Option610,313—$3.60
Option179,875—$2.84
Option16,463—$2.84

Per the Outstanding Equity Awards at Fiscal Year-End table in Rani Therapeutics Holdings, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Rani Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Talat Imran · this pageChief Executive Officer$1,052,101
Svai SanfordChief Financial Officer$946,404
Kate McKinleyChief Business Officer$943,937

Board service

Rani Therapeutics board · FY2025

How this board is paid

Company policy: Rani Therapeutics pays directors a $45,000 cash retainer. As stated in Rani Therapeutics's FY2025 proxy.

The full Rani Therapeutics compensation record

free company brief

This page is one person within Rani Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Rani Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Talat Imran's compensation dossier · One-time report. No refunds.